Biocon Limited has entered into a global settlement and license agreement with Genentech, securing earliest licensed launch dates for Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab).

The agreement resolves all pending disputes between the companies in the U.S., Canada, and other jurisdictions. This settlement enables Biocon to launch Pebrilzo in Q1 of calendar year (CY) 2027 in the European Union and UK, and in Q3 of CY 2028 in the U.S.

Launch timeline by region

The patent settlement outlines specific market entry windows for the biosimilar product across key geographies. Launches are subject to regulatory approval in each respective country or region.

Product details and mechanism

Pebrilzo is a biosimilar medicinal product where the active substance is Pertuzumab. It is a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2). By inhibiting the proliferation of tumour cells that overexpress HER2, it is used for the treatment of HER2-positive breast cancer across multiple disease stages.

What the numbers show

The phased geographic rollout indicates a strategic prioritization of high-value markets with distinct regulatory timelines. The EU and UK receive access nearly two years earlier than the U.S., reflecting the specific terms negotiated in the global settlement. The Rest of the World window spans three years (CY26-28), offering flexibility for earlier launches in certain circumstances, though other terms of the agreement remain confidential.

Biocon shares flagged a large-trade signal on the NSE, with approximately 1,057,554 shares changing hands at ₹369.20, amounting to a combined value of ₹39.04 crore.

This is a real-time large-trade signal, not a confirmed block or bulk deal. NSE/BSE publish official block and bulk deal reports only after market close — this trade may or may not appear there.

Large-trade signal details

The signal reflects a cluster of trades in Biocon shares printed within a short window at or near ₹369.20, for a combined value of ₹39.04 crore, as flagged by a real-time trade-scanning system. The activity was detected on the NSE. No buyer, seller, broker, or client identity is known or implied at this stage, as such disclosures are made only by the exchange after market close.

What this signal is, and is not

What this is, and isn't: this reflects trade-level activity — a cluster of trades in the stock above, printed within a short window at or near the quoted price, for a combined value as stated. It is generated by our real-time trade-scanning system and is not, by itself, evidence of a block or bulk deal.

A block deal has to be executed in the exchange's dedicated window (8:45–9:00am or 2:05–2:20pm), within a set price band, and above the current minimum order size (₹25 crore). A bulk deal is when one client's total trading in a stock crosses 0.5% of its equity in a single day — confirmed only once every trade that client made is added up.

Both are published by NSE/BSE after trading hours end, typically after 3:30pm — never before. If this trade qualifies as either, it will appear in the exchange's own report later today, not here first.